Metric Finance
LearnFAQ
LearnFAQ

Learn / AXSM

NASDAQ: AXSM

Axsome Therapeutics (AXSM) stock, explained like you're 5

Axsome Therapeutics trades on the Nasdaq under the ticker AXSM. It is a mid cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 8.8 billion dollars.

Ticker
AXSM
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Mid cap, about 8.8 billion dollars

Is Axsome Therapeutics a small, medium or large cap company?

No. Axsome Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 8.8 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Axsome Therapeutics makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves AXSM stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 (Stocktwits)
  • Assenagon Asset Management S.A. Sells 203,877 Shares of Axsome Therapeutics, Inc. $AXSM (MarketBeat)
  • Axsome Therapeutics (AXSM) Stock May Trade At A Discount To Growth (Simply Wall Street)
  • Axsome Therapeutics Stock: 12 Straight Red Days, Down 15% (Trefis)
  • RBC Capital reiterates Axsome Therapeutics stock rating at Outperform (Investing.com)

Follow AXSM in your daily brief

Each trading day at 5 PM ET we post what happened to Axsome Therapeutics and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow AXSM

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Axsome Therapeutics stock

What does Axsome Therapeutics do?

Axsome Therapeutics trades on the Nasdaq under the ticker AXSM. It is a mid cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 8.8 billion dollars.

What is the ticker symbol for Axsome Therapeutics?

Axsome Therapeutics trades under the ticker AXSM on the Nasdaq.

What is Axsome Therapeutics's market cap?

Axsome Therapeutics is a mid cap stock with a market cap of about 8.8 billion dollars.

How does Axsome Therapeutics make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves AXSM stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow AXSM stock every day?

Add AXSM to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow AXSM daily

A free brief on Axsome Therapeutics and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare AXSM: AXSM vs NVS, AXSM vs AZN, AXSM vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed